The available treatments, which mainly consist of inhibitors of the acetylcholinesterase (AChE) enzyme, only provide a temporary and slight improvement of the symptoms in mid- to moderate-AD patients [3,9]. The gene discussed is ACHE; the disease is Alzheimer disease.